Evidence map›Paper›PMID 33285055›Full record

ArticleCancer research and treatment2021

Risk of Death in Colorectal Cancer Patients with Multi-morbidities of Metabolic Syndrome: A Retrospective Multicohort Analysis.

Qingting Feng, Lingkai Xu, Lin Li, Junlan Qiu, Ziwei Huang, Yiqing Jiang, Tao Wen, Shun Lu, Fang Meng, Xiaochen Shu

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research and treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qingting FengDepartment of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou, China.
Lingkai XuDepartment of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou, China.
Lin LiDepartment of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou, China.
Junlan QiuDepartment of Oncology and Hematology, the Affiliated Suzhou Science and Technology Town Hospital of Nanjing Medical University, Suzhou, China.
Ziwei HuangDepartment of Orthopaedics, Orthopaedic Institute, the First Affiliated Hospital, Soochow University, Suzhou, China.
Yiqing JiangDepartment of General Surgery, Harrison International Peace Hospital, Hengshui, China.
Tao WenMedical Research Centre, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Shun LuDepartment of Radiation Oncology, Sichuan Cancer Hospital/Institute, University of Electronic Science and Technology of China, Chengdu, China.
Fang MengCentre of Systems Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Xiaochen ShuDepartment of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou, China.

Funding

Project of the Priority Academic Program Development of Jiangsu Higher Education Institutions ChinaSoochow UniversityThe Nuclear Energy Development Project 2016-1295
6 · The paper itself

Abstract

purposeThe prevalence of multi-morbidities with colorectal cancer (CRC) is known to be increasing. Particularly prognosis of CRC patients co-diagnosed with metabolic syndrome (MetSyn) was largely unknown. We aimed to examine the death risk of CRC patients according to the multiple MetSyn morbidities. MATERIALS AND

methodsWe identified CRC patients with MetSyn from the electronic medical records (EMR) systems in five independent hospitals during 2006-2011. Information on deaths was jointly retrieved from EMR, cause of death registry and chronic disease surveillance as well as study-specific questionnaire. Cox proportional hazards regression was used to calculate the overall and CRC-specific hazards ratios (HR) comparing MetSyn CRC cohort with reference CRC cohort.

resultsA total of 682 CRC patients in MetSyn CRC cohort were identified from 24 months before CRC diagnosis to 1 month after. During a median follow-up of 92 months, we totally observed 584 deaths from CRC, 245 being in MetSyn cohort and 339 in reference cohort. Overall, MetSyn CRC cohort had an elevated risk of CRC-specific mortality (HR, 1.49; 95% confidence interval [CI], 1.07 to 1.90) and overall mortality (HR, 1.43; 95% CI, 1.09 to 1.84) compared to reference cohort after multiple adjustment. Stratified analyses showed higher mortality risk among women (HR, 1.87; 95% CI, 1.04 to 2.27) and specific components of MetSyn. Notably, the number of MetSyn components was observed to be significantly related to CRC prognosis.

conclusionOur findings supported that multi-morbidities of MetSyn associated with elevated death risk after CRC. MetSyn should be considered as an integrated medical condition more than its components in CRC prognostic management.

Indexed as

MultimorbidityAdultAgedColorectal NeoplasmsFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMaleMetabolic SyndromeMiddle AgedPrevalencePrognosisProportional Hazards ModelsRegistriesRetrospective StudiesColorectal neoplasmsMetabolic syndromeMulti-morbiditiesPrognosisRisk of death

Identifiers

PMID33285055
PMCPMC8291199

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.